CADPE suppresses cyclin D1 expression in hepatocellular carcinoma by blocking IL-6-induced STAT3 activation

Anticancer Research

Volumn 30, Issue 2, 2010, Pages 481-488

  Won, Cheolhee ^a   Lee, Chang Seok ^a   Lee, Jin Ku ^a   Kim, Tack Joong ^b   Lee, Kwang Ho ^c   Yang, Young Mok ^c,d   Kim, Yong Nyun ^e   Ye, Sang Kyu ^a   Chung, Myung Hee ^a  

^a Seoul National University   (South Korea)

^b Yonsei University Wonju   (South Korea)

^c Konkuk University   (South Korea)

^d Konkuk University School of Medicine   (South Korea)

^e National Cancer Center   (South Korea)

Author keywords

CADPE; Cyclin D1; Hepatocellular carcinoma; IL 6; STAT3

Indexed keywords

3 [3,4 DIHYDROXYPHENYL]ACRYLIC ACID 2 [3,4 DIHYDROXY PHENYL]ETHYL ESTER; CAFFEIC ACID DERIVATIVE; CYCLIN D1; HISTONE H4; INTERLEUKIN 6; MUTANT PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEACETYLATION; DRUG STRUCTURE; GENE DELETION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

BLOTTING, WESTERN; CAFFEIC ACIDS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CYCLIN D1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; LIVER NEOPLASMS; LUCIFERASES; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STAT3 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED;

EID: 77950530704     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Abiru S, Migita K, Maeda Y Daikoku M, Ito M, Ohata K, Nagaoka S, Matsmoto T, Takii Y, Kusumoto K, Nakamura M, Komori A, Yano K, Yatsuhashi H, Equchi K and Ishibashi H: Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int 26: 39-45, 2006.
2. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM and Karin M: Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317: 121-124, 2007.
3. Fu M, Wang C, Li Z and Zimmers TA: Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 145: 5439-5447, 2004.
4. Tashiro E, Tsuchiya A and Imoto M: Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Sci 98: 629-635, 2007.
5. Hunter T and Pines J: Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 79: 573-582, 1994.
6. Motokura T and Arnold A: Cyclin D and oncogenesis. Curr Opin Genet Dev 3: 5-10, 1993.
7. Sherr CJ: Mammalian G-1 cyclins. Cell 73: 1059-1065, 1993.
8. Capaccio P, Pruneri G, Carboni N, Pagliari AV, Quatela M, Cesana BM and Pignataro L: Cyclin D1 expression is predictive of occult metastases in head and neck cancer patients with clinically negative cervical lymph nodes. Head Neck 22: 234-240, 2000.
9. Guo SS, Wu X, Shimoide AT, Wong J, Moatamed F and Sawicki MPJ: Frequent overexpression of cyclin D1 in sporadic pancreatic endocrine tumours. J Endocrinol 179: 73-79, 2003.
10. Langsenlehner U, Hofmann G, Samonigg H, Krippl P, Renner W and Clar H: Cyclin D1 genotype and breast cancer metastasis. Cancer Epidermiol. Biomarkers Prev 14: 1844-1845, 2005.
11. Yu Z and Weinberger PM: Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin Cancer Res 11: 1160-1166, 2005.
12. Shintani M, Okazaki A, Masuda T, Kawada M, Ishizuka M, Doki Y, Weinstein IB and Imoto M: Overexpression of cyclin DI contributes to malignant properties of esophageal tumor cells by increasing VEGF production and decreasing Fas expression. Anticancer Res 22: 639-647, 2002.
13. Driscoll B, Wu L, Buckley S, Hall FL, Anderson KD and Warburton D: Cyclin D1 antisense RNA destabilizes pRb and retards lung cancer cell growth. Am J Physiol 273: L941-L949, 1997.
14. Sauter ER, Herlyn M, Liu SC, Litwin S and Ridge JA: Prolonged response to antisense cyclin D1 in a human squamous cancer xenograft model. Clin Cancer Res 6: 654-660, 2000.
15. Shahidi F and Naczk M: Food Phenolics: Sources, Chemistry, Effects, Applications. Technomic Publishing Company, Inc., Lancaster, PA, 1995.
16. Nagaoka T, Banskota AH, Tezuka Y, Saiki I and Kadota S: Selective antiproliferative activity of caffeic acid phenethyl ester analogues on highly liver-metastatic murine colon 26-L5 carcinoma cell line. Bioorg Med Chem 10: 3351-3359, 2002.
17. Vieira O, Laranjinha J, Madeira V and Almeida L: Cholesteryl ester hydroperoxide formation in myoglobin-catalyzed low density lipoprotein oxidation: concerted antioxidant activity of caffeic and p-coumaric acids with ascorbate. Biochem Pharmacol 55: 333-340, 1998.
18. Michaluart P, Masferrer JL, Carothers AM, Subbaramaiah K, Zweifel BS, Koboldt C, Mestre JR, Grunberger D, Sacks PG, Tanabe T and Dannenberg AJ: Inhibitory effects of caffeic acid phenethyl ester on the activity and expression of cyclooxygenase-2 in human oral epithelial cells and in a rat model of inflammation. Cancer Res 59: 2347-2352, 1999.
19. Fernandez MA, Sáenz MT and García MD: Anti-inflammatory activity in rats and mice of phenolic acids isolated from Scrophularia frutescens. J Pharm Pharmacol 50: 1183-1186, 1998.
20. Jung JE, Kim HS, Lee CS, Park D, Kim Y, Lee M, Lee JW, Park J, Kim M, Ye SK and Chung MH: Caffeic acid and its synthetic derivative CADPE suppress tumor angiogenesis by blocking STAT3-mediated VEGF expression in human renal carcinoma cells. Carcinogenesis 28: 1780-1787, 2007.
21. Ye SK, Agata Y, Lee HC, Kurooka H, Kitamura T, Shimizu A, Honjo T and Ikuta K: The IL-7 receptor controls the accessibility of the TCRγ locus by STAT5 and histone acetylation. Immunity 15:813-823, 2001.
22. Balkwill F and Mantovani A: Inflammation and cancer: back to Virchow? Lancet 357: 539-545, 2001.
23. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002.
24. Karin M: Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436, 2006.
25. Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature 454: 436-444, 2008.
26. Koniaris LG, McKillop IH, Schwartzs SI and Zimmers TA: Liver regeneration. J Am Coll Surg 197: 634-659, 2003.
27. Suai K and Liu B: Regulation of JAK-STAT signalling in the immune system. Nature Rev Immunol 3: 900-911, 2003.
28. Bromberg JF: Activation of STAT proteins and growth control. BioEssays 23: 161-169, 2001.
29. Sun X, Zhang J, Wang L and Tian Z: Growth inhibition of human hepatocellular carcinoma cells by blocking STAT3 activation with decoy-ODN. Cancer Lett 262: 201-213, 2008.
30. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, Laudano A, Gazit A, LevitzkinA, Kraker A and Jove R: Constitutive activation of STAT3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20: 2499-2513, 2001.
31. Alvarez JV, Greulich H, Sellers WR, Meyerson M and Frank DA: Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res 66: 3162-3168, 2006.
32. Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC, Robbins PD, Gadiparthi S, Burke NA, Watkins SF and Grandis JR: Targeted inhibition of STAT3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci 100: 4138-4143, 2003.
33. Kanda N, Seno H, Konda Y, Marusawa H, Kanai M, Nakajima T, Kawashima T, Nanakin A, Sawabu T, Uenoyama Y, Sekikawa A, Kawada K, Suzuki K, Kayahara T, Fukui H, Sawada M and Chiba T: STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene 23: 4921-4929, 2004.
34. Qiu Z, Huang C, Sun J, Qiu W, Zhang J, Li H, Jiang T, Huang K and Cao J: RNA interference-mediated signal transducers and activators of transcription 3 gene silencing inhibit invasion and metastasis of human pancreatic cancer cells. Cancer Sci 98: 1099-1106, 2007.
35. Cui Q, Jiang W, Wang Y, Ly C, Luo J, Zhang W, Lin F, Yin Y, Cai R, Wei P and Qian C: Transfer of suppressor of cytokine signaling 3 by an oncolytic adenovirus induces potential antitumor activities in hepatocellular carcinoma. Hepatology 47: 105-112, 2008.
36. Koshihara Y, Neichi T, Murota S, Lao A, Fujimoto Y and Tatsuno T: Caffeic acid is a selective inhibitor for leukotriene biosynthesis. Biochim Biophys Acta 792: 92-97, 1984.
37. Nardini M, Scaccini C, Packer L and Virgili F: In vitro inhibition of the activity of Phosphorylase kinase, protein kinase C and protein kinase A by caffeic acid and a procyanidin-rich pine bark (Pinus marittima) extract. Biochim Biophys Acta 1474: 219-225, 2000.
38. Nardini M, Leonardi F, Scaccini C and Virgili F: Modulation of ceramide-induced NF-kappaB binding activity and apoptotic response by caffeic acid in U937 cells: comparison with other antioxidants. Free Radic Biol Med 30: 722-733, 2001
39. Lovec H, Sewing A, Lucibello FC, Müller R and Möröy T: Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: link between cell cycle control and malignant transformation. Oncogene 9: 323-326, 1994.
40. Bodrug SE, Warner BJ, Bam ML, Lindeman GJ, Harris AW and Adams JM: Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J 13: 2124-2130, 1994.
41. Lovec H, Grzeschiczek A, Kowalski M and Möröy T: Cyclin D1/bcl-1 cooperates with Myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J 13: 3487-3495, 1994.
42. Zhou P, Jiang W, Zhang YJ, Kahn SM, Schieren I, Santella RM and Weinstein IB: Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene 11: 571-580, 1995.
43. Arber N, Doki Y, Han EK, Sgambato A, Zhou P, Kim NH, Delohery T, Klein MG, Holt PR and Weinstein IB: Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res 57: 1569-1574, 1997.